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ABSTRACT
Introduction Persistent somatic symptoms (PSS) are 
common both in the general population and primary 
care. They are bothersome in terms of psychological 
and somatic symptom burden. Health professionals 
often struggle with communication, as there is a lack of 
scientifically supported explanatory models for PSS or 
a focus merely on somatic aspects of the complaints, 
which both frustrate patients’ needs. The objective of the 
present study is therefore to develop a psychoeducational 
intervention based on a current evidence- based 
explanatory model, to examine its feasibility and form the 
basis for a large- scale randomised controlled trial.
Methods and analysis In a randomised controlled 
mixed- methods pilot trial, 75 adult psychosomatic 
outpatients with PSS (duration of symptoms ≥6 months) 
and accompanying psychological (Somatic Symptom 
B- Criteria Scale total score ≥18) and somatic symptom 
burden (Patient Health Questionnaire-15 score >10) 
and no prior psychosomatic treatment will be eligible. 
Participants will be presented with either the explanatory 
model without (intervention group 1, n=25) or with 
elements of personalisation (intervention group 2, n=25). 
Participants in the control group (n=25) will receive 
information on current PSS guidelines. Participants will 
be blinded to group assignment and interventions will 
be shown on tablet computers at the outpatient clinic. 
After 1 month, qualitative follow- up telephone interviews 
will be conducted. As primary outcomes, mean changes 
in psychological and somatic symptom burden will 
quantitatively be compared between groups, respectively. 
Behavioural change mechanisms and feasibility of the 
three interventions will be evaluated using quantitative and 
qualitative measures.
Ethics and dissemination Ethics approval has been 
granted by the medical ethics board of the Hamburg 
Medical Chamber (PV5653). Results from this study will 
be published in peer- reviewed journals and presented at 
national and international conferences.
Trial registration number DRKS00018803.
INTRODUCTION
Persistent somatic symptoms (PSS) are 
marked by long- lasting (typically more than 
6 months) physical afflictions and sensations 
and include complaints associated with disor-
ders such as fibromyalgia, irritable bowel 
syndrome or somatic symptom disorder.1 
PSS are a common phenomenon both in 
the general population and medical settings. 
At the same time, treatment options are still 
limited and patients are often regarded as 
‘bothersome’ and ‘frustrating’ to work with.2 
PSS can affect every organ system and the 
estimated lifetime prevalence ranges between 
5.9% and 16.3% in the general population 
and specialised settings.3–5 In primary care, 
approximately 20% of all consultations are 
estimated to be due to PSS.6 7 PSS are often 
accompanied by psychological symptoms 
at cognitive, emotional and behavioural 
level.8–11 The term PSS in the context of this 
study summarises PSS that reach diagnostic 
threshold according to current diagnostic 
classifications (eg, somatoform disorders),12 13 
somatic symptom disorder (Diagnostic and 
Statistical Manual of Mental Disorders, Fifth 
Strengths and limitations of this study
 ► This is the first study to translate a state- of- the- art 
aetiological model for persistent somatic symptoms 
(PSS) into an explanatory model that can be used in 
daily patient care.
 ► Feedback both from a patient group and an inter-
national expert panel was used during the develop-
ment of the psychoeducational interventions, which 
employ means of visualisation and personalisation.
 ► The sample will consist of 75 patients with PSS 
in three experimental groups in order to ensure 
sufficient power for the pilot trial, using a mixed- 
methods approach.
 ► Limitations include the diverse target population 
with heterogeneous symptom profiles, thus restrict-
ing the external validity of the results.
 ► The present study is limited to a brief psychoedu-
cational intervention on a tablet computer without 
further face- to- face interaction.
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Edition/DSM-5),14 bodily distress disorder (International 
Classification of Diseases 11th Revision).15
The impairments caused by PSS affect individuals in 
terms of a significantly reduced quality of life4 and the 
healthcare system in terms of excessive healthcare costs 
due to medical consultations and diagnostic proce-
dures.16 Despite their individual and socioeconomic 
relevance, the majority of affected patients receive no 
treatment according to guidelines,17–19 thus enabling 
a chronic course of disease.20 Additionally, there is a 
considerable delay between PSS symptom onset and the 
start of an adequate treatment, that is, psychological 
interventions.21 22 Further, treatment options for PSS are 
limited and multidisciplinary treatment as well as non- 
pharmacological interventions show only moderate effect 
sizes.23 Thus, there is a great need to improve early treat-
ment in PSS.
Early interventions usually include psychoeducational 
material. While there is evidence for the general useful-
ness of psychoeducational interventions for medically 
unexplained symptoms (MUS) and functional disor-
ders,24–26 the lack of evidence- based explanatory models 
has been identified as one central barrier in the early 
treatment of PSS.27 A systematic search of MUS literature 
identified nine different explanatory models for PSS.28 
These explanatory models were based on somatosensory 
amplification, sensitisation, sensitivity, immune system 
sensitisation, endocrine dysregulation, the signal filter 
model, the illness behaviour model, autonomous nervous 
system dysfunction and abnormal proprioception, and 
also included one meta- model, the cognitive–behavioural 
therapy model. However, most of these models were only 
partly based on empirical evidence. In primary care, health 
professionals often feel insecure about the management 
of patients with PSS.2 They explain the development and 
maintenance of symptoms only vaguely, and without any 
references to current aetiological models,29–32 thereby 
failing patients’ needs for biomedical and tangible 
explanatory models.29 33–35 When symptom explanations 
and treatment are not readily available, medical doctors 
may rely on a defensive biomedical approach in dealing 
with the symptoms.19 The patients on the other hand may 
continue to search for the biomedical diagnosis which 
explains their symptoms,36 that is, examinations for short- 
time reassurance instead of actively engaging in treat-
ment, for example, with the help of knowledge of illness 
or self- management strategies.37
Recently, a new aetiological model on PSS was suggested 
by Henningsen et al.38 While historically, aetiological 
models of symptom persistence emphasised bottom- up 
processes in a biomedical context and further developed 
into a biopsychosocial understanding, this new model on 
PSS focuses on top- down processes and conceptualises 
symptoms as a perceptual dysregulation. It represents a 
comprehensive biopsychosocial model of PSS and incor-
porates evidence- based findings, that is, by enhancing 
existing vulnerability stress models and emphasising 
the role of the patients’ perception and expectations 
regarding their symptoms. The model has not yet been 
translated into an explanatory model adapted for the 
use with patients with PSS. As the authors conclude, ‘a 
major challenge remains to develop metaphors and moti-
vational techniques to convince patients to go along with 
these strategies and modify the patient’s illness belief’.38
In order to make explanatory models more accessible, 
provided information needs to be clearly formulated, 
articulated in an understandable way and avoid unnec-
essary and distracting content.39 Providing feedback 
on PSS is a peculiar challenge, as patients might feel 
disbelieved by their doctors in case a biomedical focus 
is left.27 28 Most patients have distinct preferences for 
how they would choose to receive health information, 
including the possible use of media. Visual health infor-
mation is becoming more widely used to communicate 
information about health and illness to patients. When 
used in an intervention, it can improve patients’ illness 
understanding and may ameliorate health behaviour such 
as adherence to treatment.40 As illness understanding 
requires a certain level of abstract thinking, visual infor-
mation may make these intangible processes easier to 
understand.41–43 Additionally, visual information is often 
easier to attend to and to be remembered compared with 
more traditional forms of information.44
Apart from visualisation, the provided information 
should be considered as relevant by the patient, thus 
increasing the likelihood of it being used. To increase 
individual relevance, the information has to address 
needs or fears of the individual,45 should be adjusted to 
the patients’ level of communication46 and give patients 
an active choice in the selection of the content.47 Such 
a person- centred, or personalised, approach has been 
shown to be of value for patients with long- term condi-
tions such as PSS.48
In conclusion, explanatory models for PSS are thus far 
not based on current aetiological models, existing knowl-
edge is not available in a way understandable for patients 
and their practitioners and not designed to suit indi-
vidual patient needs. However, a current state- of- the- art 
aetiological model combined with the use of active visual-
isation and personalisation might be a valuable approach 
for both patients and their practitioners to communicate 
explanatory models for PSS.
OBJECTIVES
The primary aim of the HERMES pilot study (full title: 
Helpful explanatory models in somatoform symptoms) is 
to explore the feasibility and the impact of an intervention 
formed on an evidence- based explanatory model which 
can be used as a state- of- the- art early psychoeducational 
intervention to improve the physical and psychological 
symptom burden in patients with PSS. We thus translated 
the aetiological model on PSS suggested by Henningsen 
et al into an explanatory model that fits both patients’ 
and practitioners’ needs,35 39 49 50 and that employs means 
of visualisation. Development of this explanatory model 
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was sustained by the use of feedback both by a patient 
group and an expert panel, and feasibility of the model 
will be tested in patients with PSS and their practitioners. 
Therefore, this study will serve as proof- of- concept and 
feasibility study to form the basis for a randomised 
controlled study, using explanatory models as a starting 
point to improve early treatment for patients with PSS.51 
Additionally, the present study will allow an estimation 
of randomised controlled trial (RCT) eligibility as well 
as recruitment and attrition rates. Last, the present study 
will examine the effect of this newly developed explan-
atory model both with and without elements of person-
alised medicine on psychological and physical symptom 
burden.
Study hypotheses
The primary hypothesis is that the presentation of 
explanatory models for PSS in both experimental condi-
tions results in significantly greater changes in psycholog-
ical and physical symptom burden between baseline and 
1- month follow- up compared with the control group. It 
is further explored whether the additional provision of 
choice regarding patient information leads to significantly 
greater changes in psychological and somatic symptom 
burden compared with an explanatory model without 
choice. Exploratory analyses will shed light on whether 
the presentation of explanatory models for PSS in the 
experimental conditions leads to a significantly greater 
improvements in quality of life between baseline and 
1- month follow- up compared with the control condition.
METHODS AND ANALYSIS
Study design
A pilot RCT was designed to evaluate the influence of 
evidence- based explanatory models for PSS on somatic 
and psychological symptom burden. Data will be 
collected at baseline and after 1 month. Independent 
variables will be operationalised through the exper-
imental conditions. At baseline, participants will be 
randomised into one of three experimental conditions: 
explanatory model without personalised choice versus 
explanatory model with personalised choice versus 
generic PSS information (control group). Primary 
dependent variables are psychological and physical 
symptom burden (figure 1).
Study procedures
Inclusion and exclusion criteria
Adult patients aged ≥18 years with PSS (duration ≥6 
months) and a sum score of ≥18 in the Somatic Symptom 
B- Criteria Scale (SSD-12)52 and ≥10 in the Patient Health 
Questionnaire-15 (PHQ-15)53 and thus at risk for somatic 
symptom disorder54 will be included. Written informed 
consent will be collected.
Exclusion criteria are insufficient knowledge of the 
German language, current or previous psychothera-
peutic treatment of PSS, an acute need for treatment 
due to other comorbid psychological disorders, and 
the possibility of acute self- harm or endangerment of 
others.
Figure 1 Rationale of the HERMES Study.
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Recruitment
Recruitment will take place in the psychosomatic outpa-
tient clinic of the Department of Psychosomatic Medi-
cine and Psychotherapy at the University Medical Center 
Hamburg- Eppendorf, Germany. The clinic is specialised 
in patients with depression, anxiety disorders, eating 
disorders and somatoform complaints. Patients are 
usually referred to the clinic after examinations by both 
the general practitioner (GP) and specialists. In the 
clinic, patients undergo a thorough psychosomatic eval-
uation (self- report measures and clinical interview) and 
receive assistance in the choice and finding of adequate 
treatment, as well as first clinical interventions. Eligible 
patients for the study will be verbally informed about 
the study by the attending clinician after consultation. 
Information on the study and consent will be provided 
in written form. In case of willingness to participate, 
a member of the study team will explain the course of 
the experiment in detail, answer questions and collect 
the written consent. If the patient declines to participate 
despite eligibility, the clinician will document age, sex and 
the reasons for refusal to participate. Follow- up interviews 
will be conducted via telephone 1 month after baseline.
Patient and public involvement
Patients and the public were not involved in the initial 
design of the study. During development of the interven-
tion, feedback from a patient group will be employed in 
the design of the interventions.
Randomisation
Randomisation will take place after patients are included, 
based on a random number system and an urn rando-
misation. Patients will be blinded regarding their group 
assignment.
INTERVENTION GROUPS
In order to ensure internal validity, frequency, duration 
and performance will be kept on an equal level within 
all three experimental conditions. Demonstration of the 
respective explanatory model will take place immediately 
after randomisation. Duration of all three interventions 
will be approximately 15 min each and the digital content 
will be presented on a tablet computer.
Development and design of the interventions
The explanatory model was designed around the informa-
tion contained in the aetiological model by Henningsen et 
al.38 In a first step, the aetiological model was summarised 
in a written script with the use of lay language. Then the 
script was enriched by the application of evidence- based 
feedback strategies.39 Examples of feedback strategies 
include the use of examples and metaphors, validation, 
the opportunity for comparisons with other affected 
patients and prompting statements. The script was then 
visualised according to means of active visualisation with 
two different designs, one containing stock photo images 
and the other using clip art. Information from the script 
was set to sound by a semiprofessional synchroniser and 
implemented in the digital presentation. Both versions 
were then presented to a feedback group of patients with 
PSS from a group therapy with focus on psychological 
distress primarily linked to physical complaints. After 
receiving feedback, the visual content and the script were 
adjusted accordingly, forming the first draft of the explan-
atory model. Based on this draft, all three experimental 
conditions (explanatory model without personalised 
choice vs explanatory model with personalised choice vs 
generic PSS information) were designed. These interven-
tions were then shown to an expert panel consisting of 
two members (LF and TCOH) from a European network 
on PSS (EURONET- SOMA).11 55 These experienced clini-
cians and researchers gave their feedback to the initial 
script and after an elaborated revision of the material 
approved the final versions of the three digital exper-
imental interventions, which were then rendered and 
adjusted to the use on tablet computers (for a process 
summary, see figure 2).
First experimental condition
The first experimental condition includes the aetiolog-
ical model of PSS by Henningsen et al38 translated into 
an explanatory model in a language understandable for 
both patients and healthcare professionals. Illness percep-
tions, somatosensory amplification and strategies to avoid 
symptom- related fears will be addressed within the inter-
vention. In order to further optimise the model, phrases 
from the vernacular and short summaries will be used.35 
Stigma of mental illness is tried to be minimalised.39 No 
personalised information will be implemented in the 
intervention.
Second experimental condition
In the second experimental condition, an element of 
personal choice will be added to the initial explanatory 
model. Though personalisation is generally a highly 
complex and heterogeneous matter, we tried to imple-
ment it by providing the patient with a choice concerning 
his or her individual need regarding maintaining factors 
of PSS. The first part of the explanatory model will thus 
contain information equivalent to the first intervention 
group. However, after the first part the participant will 
be asked which psychological mechanism is the most 
relevant for him or her personally: illness perceptions, 
somatosensory amplification and strategies to avoid 
symptom- related anxiety. These three aspects were chosen 
for individualisation based on their specific relevance for 
the healthcare sector.56–58 The second part of the inter-
vention will then address the specific information accord-
ingly. If the participant chooses neither of the factors, the 
information without choice from the first experimental 
condition will be shown.
Control condition
The control condition will be close to treatment as usual, 
that is, it will neither contain an explanatory model of 
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PSS, nor maintaining factors, nor personalised informa-
tion. Participants will instead receive information based 
on current guidelines for the treatment of PSS.59 The 
information addresses four levels in the treatment of 
PSS: namely, initial primary care, extended primary care, 
multimodal treatment and further psychosocial aspects.
VARIABLES AND INSTRUMENTS
Participants of all three experimental conditions will 
complete questionnaires at baseline and at 1- month 
follow- up. An overview of all instruments employed at 
baseline and follow- up is provided in table 1.
Acceptance and feasibility of the interventions
Participation and attrition rates and numerical rating 
scales on individual acceptance of the intervention and 
probability to recommend the interventions to family 
members with PSS will be used to quantitatively estimate 
acceptance and feasibility of the interventions. Addition-
ally, qualitative aspects of acceptance in terms of appli-
cability of the interventions for individual symptoms 
and satisfaction of needs will be measured using semi-
structured interviews.33–35 Expectations with regard to 
the individual course of treatment, positive and negative 
aspects of the explanatory model, issues of comprehen-
sion and general feedback will also be inquired, respec-
tively. At 1- month follow- up, participants will be asked 
which aspects of the interventions they remember and 
whether the explanatory model had any influence on 
their behaviour (ie, using the explanatory model when 
interacting with friends or family or practitioners). Inter-
views will be transcribed verbatim and qualitatively anal-
ysed applying thematic analysis as suggested by Braun and 
Clarke.60
Psychological and somatic symptom burden
Primary outcomes of the HERMES pilot study are psycho-
logical and somatic symptom burden at 1- month follow- up. 
Psychological distress due to physical symptoms will be 
measured using the SSD-12.52 The SSD-12 was developed 
to measure the psychological criteria of somatic symptom 
disorder according to DSM-5. Each of the three psycho-
logical subcriteria (cognitive, affective, behavioural) is 
measured by four items with scores ranging between 0 
and 4, resulting in a total of 12 items with a sum score 
of 0–48. The SSD-12 has good item characteristics, excel-
lent reliability (Cronbach’s α=0.95),52 61 and its ability to 
measure change over time has been established.62
The PHQ-15 measures somatic symptom burden and 
has well- established psychometric properties.63 Using 15 
items, the PHQ-15 assesses the presence and severity of 
common somatic symptoms within the last 4 weeks. A cut- 
off score of ≥10 points has been established to identify 
patients at risk for clinically relevant symptom burden. 
Its convergent and divergent validity have been tested in 
several patient samples and in the general population.53 63
In addition to the SSD-12 and PHQ-15, we also added 
two numerical Visual Analogue Scales items on subjective 
impairment in terms of the intensity of bodily symptoms 
and their interference with daily life activities over the 
past 7 days, as recommended by the EURONET- SOMA 
group.64
Psychopathological change mechanisms
Usefulness of the interventions will be measured using an 
adapted version of the Usefulness Scale for Patient Infor-
mation Material.65 The questionnaire comprises nine 
items measuring cognitive, emotional and behavioural 
usefulness of patient material. The Brief Illness Percep-
tion Questionnaire66 will indicate changes regarding 
illness perceptions. Its wide use and good psychometric 
properties could be demonstrated in a review containing 
Figure 2 Development process of the video interventions.
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data from 188 studies.67 In order to operationalise the 
concept of somatosensory amplification, the subscales 
‘catastrophising attribution’ and ‘vegetative discomfort’ 
of the Questionnaire on Body and Health (Fragebogen 
zu Körper und Gesundheit)68 will be used. Strategies to 
avoid symptom- related anxiety will be assessed with Visual 
Analogue Scales on ‘physical inactivity’ and ‘request of 
medical diagnosis’. Additionally, patients will be asked 
about functional and dysfunctional actions regarding 
their somatic complaints in the previous 2 weeks according 
to the recommendations in the German guidelines on 
functional somatic complaints in dichotomous format 
(yes vs no).59
Quality of life
Using 12 items, the 12- Item Short Form Health Survey69 
measures psychological and physical aspects of generic, 
health- related quality of life. Multiple studies could 
demonstrate its good psychometric properties.70
Sample characterisation
In order to describe the study sample, sociodemo-
graphic information on age, gender, education, cultural 









1)—4 weeks after 
baseline
Somatic symptom burden PHQ-15 X   X
Symptom- related psychological distress SSD-12 X   X
Quality of life SF-12 X   X
Depression PHQ-9 X     
Anxiety GAD-7 X     
General physical well- being VAS X X X
Illness perceptions IPQ- B X     
Avoidance behaviour VAS X   X
Control behaviour VAS X   X
Attention to symptoms VAS X   X
Physical distress last 7 days VAS X   X
Symptom influence on daily activities over the last 
7 days
VAS X   X
Catastrophising attribution FKG X     
Vegetative discomfort FKG       
Actions related to somatic symptoms HP X   X
Usefulness of patient information material USE   X   
Previous knowledge of information in intervention VAS   X   
Fit of information to individual symptoms VAS   X   
Credibility of information in intervention VAS   X   
Influence of intervention on perception of physical 
complaints
VAS   X   
Influence of intervention on course of treatment with 
GP
VAS   X   
Emotional activation due to intervention Open questions*   X   
Improvement of intervention Open questions*   X X
Remembered content of intervention Open questions*     X
Influence of intervention on perception of physical 
complaints
Open question*     X
Influence of intervention on course of treatment Open question*     X
*Qualitative measure.
FKG, Fragebogen zu Körper und Gesundheit; GAD-7, General Anxiety Disorder Questionnaire-7; GP, general practitioner; HP, actions 
according to guidelines; IPQ- B, Brief Illness Perception Questionnaire; PHQ-9, Patient Health Questionnaire-9; PHQ-15, Patient Health 
Questionnaire-15; SF-12, 12- Item Short Form Health Survey; SSD-12, Somatic Symptom B- Criteria Scale; USE, Usefulness Scale for Patient 
Information Material; VAS, Visual Analogue Scale.
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background and data on symptom onset, healthcare util-
isation over the past 4 weeks as well as current capacity 
to work and medication will be collected via the basic 
service in the outpatient clinic. Data will also include 
somatic and mental comorbidities: depression will be 
measured using the PHQ-9,53 71 anxiety via the General 
Anxiety Disorder Questionnaire-7.72 Diagnoses from the 
spectrum of mental disorders will be extracted from the 
clinical consultation referral letters.
SAMPLE SIZE/POWER CALCULATION
To our knowledge, this is the first study examining the 
influence of explanatory models on PSS and their influ-
ence on psychological and somatic symptom burden. 
Hence, there is no prior knowledge concerning sample 
size calculations. We thus used power calculation with an 
estimated drop- out rate of 25% based on a previous study 
in the same setting,73 resulting in an estimated amount 
of 25 participants per group (75 patients in total). Since 
the HERMES Study employs brief interventions, one can 
estimate a small effect size of f<0.4. In combination with 
three experimental conditions and a double sided α-error 
chance of 5%, a power of up to 78% (1−β error chance) 
can be reached, according to the respective effect size. 
Power calculations were done using the program PASS 
(V.15.0.3) and an analysis of covariance (ANCOVA) as 
statistical measure.
Handling of missing values
Participants with ≥25% missing baseline scores will not 
be included in the study. In case of missing data either at 
baseline or follow- up, cases will be analysed according to 
intention- to- treat principles if a minimum of 75% of data 
are present. Handling of missing data will be adapted to 
missing data patterns. If patients are not available for the 
interviews at 1- month follow- up, they will be registered as 
drop- outs after at least five attempts of being reached via 
telephone. Reason for drop- out will be recorded and only 
baseline information will be used for analysis. Systematic 
differences between participants and drop- outs will be 
examined using the provided data.
Statistical analyses
Since normal distribution can be assumed for sum 
scores of symptom burden (psychological symptom 
burden=SSD-12, somatic symptom burden=PHQ-15), 
mean score and SD can be used as descriptive character-
istic. For evaluation of the primary hypothesis, namely the 
positive effect of presenting an explanatory model on both 
psychological and somatic symptom burden, an ANCOVA 
with experimental group (explanatory model without vs 
explanatory model with personalised choice vs generic 
PSS information) as independent variable and changes 
in symptom burden at 1- month follow- up as dependent 
variables (psychological=∆SSD-12; somatic=∆PHQ-15) 
will be employed, with covariates being age, gender 
and symptom burden at baseline. Additionally, post- hoc 
analysis will be used for global comparison of the three 
experimental conditions. Results will be reported using 
adjusted mean differences with corresponding 95% CIs 
and p values. Statistical analysis will be performed using 
IBM SPSS V.23.0. Mediation analysis will be employed for 
answering the exploratory question concerning mecha-
nisms of action (perceived usefulness of the intervention, 
illness perceptions, somatosensory amplification, strat-
egies to avoid symptom- related anxiety, and functional 
and dysfunctional actions regarding somatic complaints) 
between explanatory model and changes in psychological 
and somatic symptom burden at 1- month follow- up, using 
the SPSS macro PROCESS.74 Qualitative analysis will be 
conducted using thematic analysis according to Braun 
and Clarke.60
Methods to reduce bias
Selection bias is minimised by the inclusion of a control 
group and an urn randomisation. Presentation of the 
interventions will be completely standardised by the use of 
videos on tablet computers. The videos have been created 
with the attempt to maximise comparability in terms of 
length, amount of content and visual representation. 
Both participants and interviewers at 1- month follow- up 
will be blinded regarding the experimental condition. As 
it is not possible to blind the scientific assistant during 
intervention, follow- up interviews will be conducted by 
an interviewer blinded with regard to the experimental 
condition. The rate of participants who refrain from 
signing an informed consent (ie, non- response rate) 
will be reported. The full recruitment process will be 
documented according to Consolidated Standards of 
Reporting Trials reporting standards.75
Study registration
The study was registered at the German Clinical Trials 
Register (Deutsches Register Klinischer Studien),76 and 
thereby automatically submitted to the WHO Interna-
tional Clinical Trials Registry Platform.
Ethics and dissemination
The study procedure was reviewed and approved by the 
medical ethics board of the Hamburg Medical Chamber 
(approved on 23 October 2017; PV5653). Results from 
this study will be published in peer- reviewed journals and 
presented at national and international conferences. 
Before participation, patients will receive detailed infor-
mation about the nature, purpose and possible conse-
quences of the trial. Participants will be required to give 
written informed consent to participate in the study.
DISCUSSION
The HERMES pilot study aims at developing an evidence- 
based and visualised explanatory model for PSS, to esti-
mate effect sizes of its influence on both psychological and 
somatic symptom burden and to evaluate feasibility and 
acceptance of the intervention. It is hypothesised that the 
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presentation of the explanatory model to patients with 
PSS will result in significant changes in psychological and 
somatic symptom burden compared with a control group 
and further, that an additional personalisation through 
choice of information will lead to an even greater change. 
Furthermore, we also will explore whether the explana-
tory models will foster greater improvements in quality of 
life between baseline and 1- month follow- up compared 
with the control condition.
Explanatory models are not only part of psychotherapy/
patient- activating treatments, yet form the basis for an 
individual understanding of complaints. They might thus 
for example help GPs in their role as gatekeeper within 
the health system and should easily be employed in early 
interventions.37 By ensuring a high scientific standard in 
the development and the content of the intervention, we 
want to fill the void of evidence- based explanatory models 
for PSS. While there is a number of useful clinical tools 
and verbalisations available, the majority is limited to 
clinical use and has not been reviewed within research.28 
Additionally, we are to our knowledge the first to system-
atically evaluate an explanatory model for PSS that has 
been developed using means of active visualisation and 
personalisation.41 42 48
In spite of the numerous advantages of the planned 
investigation and the high demand for evidence- based 
explanatory models for PSS, some limitations have to be 
considered: Visualisation and wording of an intervention 
are always bound to a subjective nature, and will thus never 
appeal to all patients. However, by employing a patient 
feedback group, we will try to minimalise this effect during 
development of the intervention and use qualitative data 
for further improvement after the trial. By employing an 
animated intervention and tablet computers, we are argu-
ably also at risk of entering ‘unfamiliar territory’ for the 
patients when it comes to clinical interventions. However, 
the technological advancements and user data of the past 
centuries support this change of therapeutic paradigm 
rather than restraining from it.77–79 From a methodolog-
ical point of view, we are aware that the employed person-
alisation will be of limited external value in regard to the 
extremely heterogeneous group of patients with PSS, and 
as they considerably differ in terms of patients’ history, 
complaints and attitudes towards (psycho)therapeutic 
approaches. These limitations notwithstanding, we hope 
to ensure a first insight of the added value of this patient- 
centred approach in order to foster both effectiveness 
and appeal of the explanatory model.
If proven effective, the planned interventions will make 
an important contribution to the early treatment of PSS. 
They might thus form the basis for the much needed 
additional research within this area. Future trials might 
increasingly incorporate concepts of blended interven-
tions, combining various psychoeducational delivery 
methods. Our use of tablet computers might repre-
sent one possible delivery method. Analysis of our data 
will further provide insight into whether our choice of 
personalisation is valid or if for example more complex 
algorithms or the use of psychometrical data might be 
more suitable approaches.
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